190 results on '"Festino, Lucia"'
Search Results
2. Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma
3. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
4. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
5. Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients
6. IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
7. Management of cutaneous melanoma: radiologists challenging and risk assessment
8. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
9. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
10. Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma
11. Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors
12. 1247 Gene signature predict autoimmune toxicity in patients with metastatic melanoma
13. 579 Evaluation of cemiplimab treatment duration: clinical outcomes in advanced CSCC
14. 42 IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy – a deep biomarker analysis
15. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era
16. Safety of extended interval dosing immune checkpoint inhibitors:a multicenter cohort study
17. Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study
18. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors
19. Immunotherapy Assessment: A New Paradigm for Radiologists
20. Contributors
21. Molecular Mechanisms Underlying the Action of Ipilimumab Against Metastatic Melanoma
22. Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors
23. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care
24. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
25. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
26. 21 IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy – a real life study
27. Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis
28. 842 Development of a multiplex test for predicting response to combined immunotherapies in patients with metastatic melanoma
29. PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
30. Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhance immune activity: a gene profiling retrospective analysis
31. Extended interval dosing in patients with cancer receiving immune checkpoint inhibitors: Safety analysis from the EDICI study.
32. Efficacy and safety of "second adjuvant" therapy with BRAF/MEK inhibitors after resection of recurrent melanoma following adjuvant PD-1–based immunotherapy.
33. Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients.
34. 24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome
35. 308 Transcriptomic analysis of melanoma patients in adjuvant setting treated with anti PD1 therapy: real life study
36. 934 Biological mechanisms in the different etiologies of Merkel cell carcinoma patients: polyomavirus or UV exposure
37. Dermatologic adverse events associated with targeted therapies for melanoma
38. Clinical Categorization Algorithm (Clical) and Machine-Learn- ing Approach (Srf-clical) to Predict Clinical Benefit to Immuno- therapy in Metastatic Melanoma Patients: Real-world Evidence from Istituto Nazionale Tumori Irccs Fondazione Pascale, Na- poli, Italy
39. Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
40. Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes’ iTNF-α Expression
41. Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience
42. Management of EGFR-mutant non-small-cell lung cancer patients after first-line reversible EGF receptor-tyrosine kinase inhibitors
43. PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab.
44. Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma
45. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
46. 761 Potential predictive biomarkers of rapid progression and response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients
47. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
48. Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy
49. Correlation of nivolumab 480 mg Q4W with better survival than other nivolumab monotherapy schedule in metastatic melanoma patients.
50. Identification of potential predictive biomarkers of rapid progression and rapid response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.